AstraZeneca In Buy Now, Pay In Full Later Deal For Majority Acerta Stake
This article was originally published in Scrip
In a move which AstraZeneca PLC says "completes its transformation in oncology," it is acquiring a 55% stake in privately held Dutch biotech Acerta Pharma BV for $4bn, made up of $2.5bn now and $1.5bn later. The deal also includes an option to acquire the remainder of the company for a further $3bn.
You may also be interested in...
Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Finance Watch: BioGeneration Ventures, Autobahn Labs Offer New Start-Up Resources
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
Positive CLL Data For AstraZeneca's BTK Inhibitor Prompts Early ASCEND Trial End
The Calquence Phase III ASCEND trial met its primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukemia and thus will stop early.